Concepedia

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

Zheng Wang, Jia Fan, Shao‐Lai Zhou, Yun‐Fan Sun, Fei Liang, Yuan Ji, Fangming Gu, Tao Li, Li Peng, Tao Peng,

The Lancet · 2025 · 37 citations · 24 references

DOI

Concepts

References

24

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Amit G. Singal, Josep M. Llovet, Mark Yarchoan et al. · Hepatology · 2023 · 1.7K citations · Full text

, , +17

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Heather A. Wakelee, Moïshe Liberman, Terufumi Kato et al. · New England Journal of Medicine · 2023 · 1K citations · Full text

, , +17

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel, Megan Othus, Yuanbin Chen et al. · New England Journal of Medicine · 2023 · 827 citations · Full text

, , +17

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 744 citations

, , +16

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · New England Journal of Medicine · 2023 · 682 citations · Full text

, , +17